Sanofi: FDA Grants Fast Track Designation For SAR402663

(RTTNews) - Sanofi said the FDA has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration. Sanofi is currently evaluating SAR402663 in a phase 1/2 for the treatment of patients with neovascular AMD. SAR402663 delivers genetic material encoding soluble FLT01 designed to inhibit vascular endothelial growth factor.

The fast-track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need.

For More Such Health News, visit rttnews.com.